Stat3 pathway inhibitors and cancer stem cell inhibitors
The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrant Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
1. A compound selected from the group consisting of:
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.
2. A compound of formula VII:
each R 1 is hydrogen;
R 3 is C 1-6 ;
R 7 is C 1-6 alkyl substituted with 1 to 4 halogen substituents; and
n is 1-4.
3. A pharmaceutical composition comprising a compound or a pharmaceutically-acceptable salt thereof as claimed in any one of claims 1 or 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, carrier, or diluent.